【摘要】 目的评价高强度聚焦超声(HIFU)联合内分泌治疗前列腺癌(PCa)的疗效和副作用。方法PCa患者65例,B期12例,C期32例,D期21例,平均PSA为(85.5±79.4)ng/ml;以HIFU联合内分泌治疗,随访PSA和1、3、5年生存率,观察治疗的副作用。结果55例获得12～46个月的随访;术后3个月平均PSA为(53.4±51.3)ng/ml,与术前相比具有显著性差异(P<0.01),患者1、3、5年生存率分别为87.2%、38.2%和23.6%,副作用轻微。结论HIFU联合内分泌治疗前列腺癌能有效地降低PSA,提高患者生存率,具有高度安全性。更多还原

【Abstract】 Objective To evaluate the efficafy and side-effect of high intensity focused ultrasound (HIFU) combined with hormone in treatment of prostatic carcinoma. Methods A total of 65 cases with prostatic carcinoma were recruited in this study including 12 cases of stage B, 32 cases of stage C and 21 cases of stage D. The average level of serum PSA was (85.5±79.4)ng/ml. All the patients were treated with the combination therapy. The level of serum PSA and 1,3,5 year survival rate were followed and side-effects of the treatment were investigated. Results Fifty-five cases were followed from 12 months to 46 months. The average level of PSA was (53.4±51.3)ng/ml 3 months after therapy ,Compared with that before treatment, the level of serum PSA decreased significantly (P<0.01).1,3,5 year survival rate were 78.2%、28.8% and 25%, respectively. The side-effects were slight. Conclusion HIFU combined with hormone for treatment of prostatic cancinoma could reduce the level of serum PSA and improve the middle and long-term survival rates with high safety. It will provid a new treatment for postatic carcinoma.更多还原